-
Cancer Treatment Reviews Sep 1983
Clinical Trial Review
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Female; Humans; Kidney Neoplasms; Kinetics; Male; Megestrol; Megestrol Acetate; Prostatic Neoplasms; Uterine Neoplasms
PubMed: 6352021
DOI: 10.1016/0305-7372(83)90029-4 -
The American Journal of Geriatric... Jun 2020
Topics: Drug Therapy, Combination; Humans; Megestrol; Megestrol Acetate; Mental Disorders
PubMed: 32122805
DOI: 10.1016/j.jagp.2020.01.188 -
Cancer Treatment Reviews Mar 1989
Comparative Study Review
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Renal Cell; Contraceptive Agents, Male; Contraceptives, Oral; Endometrial Hyperplasia; Female; Humans; Kidney Neoplasms; Male; Megestrol; Megestrol Acetate; Melanoma; Middle Aged; Ovarian Neoplasms; Prostatic Hyperplasia; Prostatic Neoplasms; Rabbits; Tamoxifen; Uterine Neoplasms
PubMed: 2471590
DOI: 10.1016/0305-7372(89)90004-2 -
Medicina Clinica Mar 2022
Topics: Adolescent; Adrenal Insufficiency; Child; Humans; Hydrocortisone; Megestrol; Megestrol Acetate
PubMed: 34074479
DOI: 10.1016/j.medcli.2021.04.019 -
International Journal of Nanomedicine 2006The aim is to review major clinical trials that have used megestrol acetate (MA) in the treatment of cachexia across several disease states. A review of general usage... (Review)
Review
The aim is to review major clinical trials that have used megestrol acetate (MA) in the treatment of cachexia across several disease states. A review of general usage and potential side-effects are discussed. A theory that the newly approved nanocrystal formation of MA can better deliver this potent medication for treatment will also be reviewed.
Topics: Anorexia; Cachexia; Clinical Trials as Topic; Drug Carriers; Humans; Megestrol Acetate; Nanoparticles
PubMed: 17722275
DOI: 10.2147/nano.2006.1.4.411 -
IARC Monographs on the Evaluation of... Dec 1979
Topics: Animals; Carcinogens; Chemical Phenomena; Chemistry; Dogs; Female; Humans; Male; Megestrol; Mice; Rats
PubMed: 296136
DOI: No ID Found -
Oncology 1992Although current hormonal therapy of prostate cancer may not appear to have altered survival appreciably, there have been considerable changes that may significantly... (Review)
Review
Although current hormonal therapy of prostate cancer may not appear to have altered survival appreciably, there have been considerable changes that may significantly affect the future management of this disease. A number of new hormonal agents have been introduced that still require definition of their therapeutic efficacy. Megestrol acetate, a hormonal agent with multiple sites of action in androgen metabolism, has recently been investigated in the treatment of patients with metastatic and locally advanced disease, and in those patients whose disease progresses with other hormonal therapies. Megestrol acetate plus mini-dose diethylstilbestrol (DES) is associated with fewer side effects than standard-dose DES and has equivalent therapeutic efficacy in the treatment of patients with metastatic disease. In patients with locally advanced disease that may benefit from hormonal cytoreduction, megestrol acetate is effective and well tolerated. Megestrol acetate has a role in the palliation of patients with progressive disease despite initial hormonal therapy. Considerable controversy surrounds the therapy of carcinoma of the prostate; further studies are required to define optimal hormonal therapy.
Topics: Diethylstilbestrol; Drug Therapy, Combination; Humans; Male; Megestrol; Megestrol Acetate; Neoplasm Metastasis; Prostatic Neoplasms
PubMed: 1461622
DOI: 10.1159/000227123 -
The Senior Care Pharmacist Jul 2022To evaluate the efficacy and safety of megestrol for off-label use in older patients with weight loss. Retrospective, nonblinded cohort study. Upstate University...
To evaluate the efficacy and safety of megestrol for off-label use in older patients with weight loss. Retrospective, nonblinded cohort study. Upstate University Hospital is a 420-bed facility and academic medical center with a level 1 trauma center. Upstate Community Hospital is a 314-bed acute care/hospital/ambulatory care center and long-term care hospital that also provides teaching services. Patients 65 years of age and older without malignancy or acquired immunodeficiency syndrome who were initiated and continued megestrol therapy at the Upstate University hospitals for at least two weeks were included. Of the 1,290 patients initially screened, 16 patients on megestrol were evaluated. An age- and gender-matched control group of 16 patients was utilized for comparison of changes in weight and other variables. Patients in the megestrol group have received daily doses of megestrol between 160 mg to 800 mg for an average duration of 19 days. Patients in the control group had no history or current use of megestrol utilization. The primary outcome was an increase in weight. Secondary outcome measures included albumin and thromboembolic events. Changes in weight and albumin were also compared with the control group. At a mean duration of 19 days, there was no significant difference in weight gain (0.95 kg, OR = 1.33 [95% CI -1.615-3.527]). Albumin decreased by (0.4 g/dL OR = 0.916 [95% CI 0.12-0.78]) and none of the patients developed a thromboembolic event. In older hospitalized patients, megestrol did not increase weight, and did not improve albumin. No thromboembolic events were observed, but this may be because of a limited duration of observation of therapy and the routine use of anticoagulation prophylaxis in the inpatient setting.
Topics: Aged; Albumins; Cohort Studies; Hospitalization; Humans; Megestrol; Retrospective Studies
PubMed: 35752918
DOI: 10.4140/TCP.n.2022.284 -
The Annals of Pharmacotherapy Oct 2001To report a case of Cushing syndrome associated with megestrol acetate therapy in a patient with renal insufficiency.
OBJECTIVE
To report a case of Cushing syndrome associated with megestrol acetate therapy in a patient with renal insufficiency.
SUMMARY
A 17-year-old boy with renal insufficiency due to unilateral renal agenesis developed Cushing syndrome and worsening of his renal function after megestrol acetate therapy. The diagnosis was based on clinical and analytical evaluation.
DISCUSSION
Megestrol acetate is indicated for the treatment of cachexia associated with AIDS and malignancy. Due to its glucocorticoid activity, megestrol use has resulted in the occurrence of Cushing syndrome in both patient groups. We report the case of a young patient with renal insufficiency due to unilateral renal agenesis who developed Cushing syndrome two months after administration of high-dose (900-mg/d) megestrol acetate for an eating disorder.
CONCLUSIONS
The risk of megestrol-induced Cushing syndrome, especially with high doses of the medication, should be considered as a possible adverse effect in patents with renal insufficiency.
Topics: Adolescent; Cushing Syndrome; Feeding and Eating Disorders; Humans; Kidney Diseases; Male; Megestrol; Metabolic Clearance Rate; Progesterone Congeners
PubMed: 11675847
DOI: 10.1345/aph.10197 -
Nutrition in Clinical Practice :... Jun 1993Anorexia and involuntary weight loss are prevalent problems in oncology and AIDS patients. Cytokines are suspected but not proven causes of cachexia. Megestrol acetate... (Review)
Review
Anorexia and involuntary weight loss are prevalent problems in oncology and AIDS patients. Cytokines are suspected but not proven causes of cachexia. Megestrol acetate has been found to increase appetite, food intake, and weight in randomized, placebo-controlled trials in patients with advanced malignancies and in patients with AIDS. This hormone derivative probably has both central nervous system and peripheral metabolic effects. No significant effect on survival has been demonstrated in these trials. The optimal dose for appetite enhancement is unknown; we have chosen 320 mg/d as our initial dose. Megestrol acetate is usually well tolerated, and it may be helpful in the symptomatic and palliative therapy of patients with anorexia and weight loss.
Topics: Acquired Immunodeficiency Syndrome; Anorexia; Cachexia; Clinical Trials as Topic; Humans; Megestrol; Megestrol Acetate; Neoplasms
PubMed: 8289758
DOI: 10.1177/0115426593008003115